Unfractionated heparin: Focus on a high-alert drug

被引:0
|
作者
Niccolai, CS
Hicks, RW
Oertel, L
Francis, JL
机构
[1] Univ Pharmacotherapy Associates LLC, Monroeville, PA 15146 USA
[2] US Pharmacopeia, Rockville, MD USA
[3] Massachusetts Gen Hosp, Anticoagulat Management Serv, Boston, MA 02114 USA
[4] Florida Hosp, Ctr Thrombosis & Hemostasis, Orlando, FL USA
来源
PHARMACOTHERAPY | 2004年 / 24卷 / 08期
关键词
unfractionated heparin; medication errors; drug-related problems; heparin-induced thrombocytopenia; bleeding events; osteopenia;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Unfractionated heparin (UFH) is associated with a high rate of drug-related problems due to either its inherent pharmacologic properties or an extension of these properties often caused by medication errors. The drug-related problems associated with UFH can significantly hinder the success of therapy and negatively affect the overall cost of care. Unfractionated heparin has been classified as a high-alert drug by the Institute for Safe Medication Practices. Approximately 2.1% of the total records submitted to the MedMARx national error database were related to UFH; 4.5-5.5% of these errors reported were harmful. With this high potential for error, it is essential that all health care providers adopt a collaborative or systems approach to identify solutions to reduce the occurrence of these medication errors. The joint Commission on Accreditation of Healthcare Organizations has published national patient safety goals for improving the safety of patient care, many of which are applicable to UFH therapy. Unfractionated heparin drug-related problems not necessarily related to medication errors include heparin-induced thrombocytopenia, bleeding events, and osteopenia. Heparin-induced thrombocytopenia is a serious complication of heparin therapy and remains seriously undiagnosed. Bleeding events often occur with therapeutic as well as prophylactic UFH administration even when monitoring indexes are within the therapeutic range. However, due to the variability associated with UFH monitoring methods, definitive guidelines are lacking to assist in avoiding such serious events. Osteopenia has been associated with long-term UFH therapy; one third of patients experience reductions in bone density, potentially leading to fractures. Today, safer alternative anticoagulation therapies are available, such as the low-molecular-weight heparins. When compared with UFH, these alternative therapies provide equivalent or superior efficacy for numerous indications.
引用
收藏
页码:146 / 155
页数:10
相关论文
共 50 条
  • [41] HIGH AND LOW AFFINITY HEPARIN COMPARED WITH UNFRACTIONATED HEPARIN AS ANTITHROMBOTIC DRUGS
    MERTON, RE
    THOMAS, DP
    HAVERCROFT, SJ
    BARROWCLIFFE, TW
    LINDAHL, U
    THROMBOSIS AND HAEMOSTASIS, 1984, 51 (02) : 254 - 256
  • [42] Drug-Drug Interactions Involving High-Alert Medications that Lead to Interaction-Associated Symptoms in Pediatric Intensive Care Patients: A Retrospective Study
    Kiesel, Lisa Marie
    Bertsche, Astrid
    Kiess, Wieland
    Siekmeyer, Manuela
    Bertsche, Thilo
    Neininger, Martina Patrizia
    PEDIATRIC DRUGS, 2024, 26 (05) : 619 - 629
  • [43] Nurses' perceptions of high-alert medication administration safety: A qualitative descriptive study
    Sessions, Laura C.
    Nemeth, Lynne S.
    Catchpole, Kenneth
    Kelechi, Teresa J.
    JOURNAL OF ADVANCED NURSING, 2019, 75 (12) : 3654 - 3667
  • [44] High-Alert Medication Stratification Tool-Revised Phase II: A Multisite Study Examining the Validity, Interrater Reliability, and Ease of Use of the High-Alert Medication Stratification Tool-Revised
    Shenk, McKenzie R.
    Washburn, Natalie C.
    Stephens, Sarah S.
    Burger, Gregory P.
    Curtis, James M.
    Henney, Jessalynn K.
    McCarthy, Jamie L.
    Degenkolb, Kerri E.
    Fritschle, Andrew C.
    Macik, Monica R.
    Dossett, Heather A.
    Walroth, Todd A.
    JOURNAL OF PATIENT SAFETY, 2021, 17 (08) : E1697 - E1706
  • [45] Incidence of drug-related adverse events related to the use of high-alert drugs: A systematic review of randomized controlled trials
    Menezes, Michelle Santos
    Doria, Grace Anne Azevedo
    Valenca-Feitosa, Fernanda
    Pereira, Sylmara Nayara
    Silvestre, Carina Carvalho
    de Oliveira, Alfredo Dias
    Lobo, Iza Maria Fraga
    Quintans-Junior, Lucindo Jose
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2024, 14
  • [46] Medi-Dose/EPS Announces New High-Alert Line Tracing Label
    不详
    JOURNAL OF INFUSION NURSING, 2011, 34 (04) : 272 - 272
  • [47] Harm Prevalence Due to Medication Errors Involving High-Alert Medications: A Systematic Review
    Sodre Alves, Barbara Manuella Cardoso
    de Andrade, Tamara Natasha Gonzaga
    Cerqueira Santos, Sabrina
    Goes, Aline Santana
    Santos, Adriano da Silva
    de Lyra Junior, Divaldo Pereira
    de Oliveira Filho, Alfredo Dias
    JOURNAL OF PATIENT SAFETY, 2021, 17 (01) : E1 - E9
  • [48] A Multicenter, Multidisciplinary, High-Alert Medication Collaborative to Improve Patient Safety: The Singapore Experience
    Khoo, Ai Leng
    Teng, Monica
    Lim, Boon Peng
    Tai, Hwei Yee
    Lau, Tang Ching
    JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 2013, 39 (05): : 205 - 212
  • [49] Pediatric High-Alert Medications: Evidenced-Based Safe Practices for Nursing Professionals
    Faber, RoseMarie
    CRITICAL CARE NURSE, 2009, 29 (01) : 88 - 88
  • [50] Impact of a clinical decision support system for high-alert medications on the prevention of prescription errors
    Lee, JaeHo
    Han, Hyewon
    Ock, Minsu
    Lee, Sang-il
    Lee, SunGyo
    Jo, Min-Woo
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2014, 83 (12) : 929 - 940